Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness of abatacept, rituximab or second anti-TNF alpha in rheumatoid arthritis
2008-005450-20Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of abatacept, rituximab, infliximab, adalimumab and etanercept in rheumatoid arthritis (RA) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Baseline-adjusted mean DAS28 score, EQ-5D score at 12 months and 1 more. Started Oct 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-005450-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005450-20.